Exclusive Invitation for Drug Discovery Leaders!

Genomics is a pioneering precision medicine company that uses large-scale genetic information to develop innovative precision healthcare tools and bring new understanding to drug discovery. We were formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford. Today, we are collaborating with some of the world’s leading biopharmaceutical companies and helping them to predict, prevent, treat, and cure—dramatically reducing the human and financial cost of common diseases like cancer, diabetes, and heart disease.

American Pharmaceutical Review is the leading review journal for business and technology in the pharmaceutical industry throughout North America since 1998. Published seven times a year, APR provides unbiased editorial on topics such as drug delivery, information technology, research & development, analytical development and control, equipment and facility manufacturing, and regulatory affairs. Each issue offers American Pharmaceutical Review's 40,000 readers of senior executives, technical personnel, scientists, and others fully abreast of the latest trends and developments in the process of pharma/biopharma manufacturing.

Pharmaceutical Outsourcing is a publication journal dedicated to pharmaceutical and biopharmaceutical outsourcing and contract services since 2000. With regular coverage on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, PO brings complete coverage of trends and issues in the industry. Published four times a year, each issue offers Pharmaceutical Outsourcing's 20,000 readers of senior executives, technical personnel, scientists, and others fully abreast of the latest trends and developments in pharma/biopharma outsourcing and services market.

For over 30 years, Evotec has offered comprehensive drug discovery and development solutions, guiding projects from target identification to the clinic. We integrate deep disease understanding, a multimodality approach, advanced technologies, and tailored solutions to enhance the probability of success. Our innovative and flexible approach supports collaboration through standalone CRO/CDMO services, integrated drug discovery and development programs, or strategic partnerships, regardless of your stage in the discovery-development journey. Evotec's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence.

Pelago Bioscience supports drug discovery teams with our patented CETSA® (Cellular Thermal Shift Assay) technology, delivering biologically relevant insights directly from natural cell environments. As the pioneers of CETSA, we provide fast, actionable data to minimize risks, prioritize compounds, and drive progress. With services tailored to your goals, we’re more than a CRO—we’re your dedicated partner in advancing your drug discovery journey with confidence and precision.

Appsilon empowers Fortune 500 companies to leverage open-source technology for faster, data-driven decision-making in regulated environments, driving innovation and advancing industry standards. For over a decade, we have delivered applications using Shiny for Python and R to seven out of ten leading biopharma companies, technology innovators like Elkem, and various non-profit organizations. Our dashboards serve as robust, user-friendly tools that enhance drug discovery, streamline clinical trials, and improve operational efficiency across the pharmaceutical and healthcare sectors and beyond. Our services integrate software excellence with high-quality data analysis, AI and machine learning innovations, and scalable infrastructure to transform data into impactful solutions focused on accuracy, scalability, and reliability. We actively contribute to the growth of the open-source Shiny community by developing new packages, sharing knowledge, and participating in and organizing events, including the largest online conference for Shiny enthusiasts, ShinyConf.

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies.

Since joining Amgen R&D in 2018, Zoran Krunic has been at the forefront of applying Machine Learning to enhance patient outcomes and streamline clinical trial enrollment processes, utilizing comprehensive Electronic Health Records and clinical datasets. His pioneering work in the Quantum Machine Learning space, in collaboration with IBM's Quantum team, has been instrumental in integrating machine learning with quantum computing through IBM’s Qiskit platform. Building on these foundations, Zoran has broadened his research scope to deepen the study of quantum kernels, scrutinizing their effects on the variability and reproducibility of small clinical datasets. Additionally, he has launched several innovative projects within the quantum computing sphere. These initiatives go beyond quantum kernels, delving into various facets of Quantum Machine Learning (QML) and the wider Quantum Computing disciplines, all aimed at advancing the integration of Quantum Computing within pharmacology. Prior to his tenure at Amgen, Zoran developed Machine Learning algorithms at Optum to predict hardware and software failures within complex enterprise architectures. He has a strong background in data engineering and systems development, having contributed significantly to large-scale projects at renowned organizations such as Capital Group and ARCO Petroleum. In his current full and part-time endeavors, Zoran is leading the efforts in embracing generative AI technologies, with a particular focus on OpenAI's GPT and Anthropic's Claude models. His work is focused on prompt engineering and its application to code generation, advanced document analysis, and process management, with a commitment to ethical AI practices and data privacy. Most recently, the work has expanded to include reproducibility and the potential for auto-labeling using generative AI. A recognized voice in quantum computing circles, Zoran is a regular presenter at industry conferences and has served on numerous panels discussing the integration of quantum computing and generative AI within the Health Sciences sector, with a firm belief that the integration of these new technologies will be deep and comprehensive. With a Master of Science in Electrical Engineering & Computer Science, Zoran continues to explore and contribute to the evolving relationship between quantum computing and artificial intelligence, fostering groundbreaking advancements in healthcare technology.

Patrick Neal is a Cheminformatics Analyst working for GSK on DNA Encoded Library (DEL) technologies. During his undergraduate degree, he worked in computational chemistry with Professor Steven Lopez at Northeastern University doing materials photo-pharmacology research using quantum chemistry. Patrick now works on building efficient and scalable drug discovery pipelines that leverage big data systems combined with novel cheminformatic tools to impact effective hit calling on DEL screens.

Based in Cambridge, UK, DefiniGEN specializes in providing advanced human cell products and disease models derived from induced pluripotent stem cells (iPSCs). Our offerings include:

• Opti-HEP: Fully functional iPSC-derived hepatocyte models designed for generating pre-clinical human data, aiding in liver research and toxicology studies.
• Disease Modeling: In vitro liver and metabolic disease models, including those for MASLD, A1ATD, Wilson's Disease, and Ornithine Transcarbamylase Deficiency, facilitating the study of disease mechanisms and therapeutic development.
• Efficacy and Toxicology Screening: Platforms for assessing the efficacy and safety of therapeutic candidates, supporting drug discovery and development processes.

These products and services support drug discovery, toxicology screening, and disease research by providing reliable, human-relevant cell models.

Fovus is revolutionizing cloud-based supercomputing for drug discovery and development. Our platform delivers computational insights up to 100x faster while cutting costs by over 80%, enabling biotech and pharma teams to accelerate innovation and reduce time to market. With proven success in optimizing workflows and enhancing efficiency, we empower scientists to focus on breakthroughs rather than infrastructure challenges. Visit us to explore how Fovus can transform your computational strategies and drive impactful results for your organization.

LGC - Your Trusted Partner for Reference Standards

For over 40 years, LGC has been at the forefront of complex organic synthesis, providing high-quality products and services to meet demanding analytical needs. Backed by a catalogue of over 150,000 compounds and industry-leading expertise in stable isotope-labelled (SIL) materials, we provide tailored solutions to support your goals.

Our product portfolio includes API standards, metabolites, impurities, and endogenous compounds, available in native and SIL forms.

Our Specialities:

• Toxicology support: Enabling trace-level analysis and pharmacokinetic studies with bulk synthesis of drug standards and development of SIL materials.
• Custom synthesis: Bespoke synthetic solutions to accelerate lead optimisation.
• Bespoke productions: Flexible unit sizes, customisable Certificates of Analysis, pharmacopeia traceability, and worldwide inventory management.

At LGC, we are committed to being your trusted partner, delivering essential products and services to advance drug discovery, safety evaluations, and pharmaceutical manufacturing.

LGC – Science for a Safer World